How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?

European Urology

Volumn 60, Issue 3, 2011, Pages 431-433

  Sylvester, Richard J ^a  

^a EORTC Headquarters ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

BLADDER CARCINOMA; BLADDER SURGERY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CARCINOMA IN SITU; CLINICAL PRACTICE; CYSTOSCOPY; DRUG EFFICACY; EDITORIAL; EXTERNAL VALIDITY; FOLLOW UP; GENE EXPRESSION; HUMAN; LONG TERM CARE; NON MUSCLE INVASIVE BLADDER CANCER; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TRANSURETHRAL RESECTION OF BLADDER TUMOR;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 79960996987     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.001     Document Type: Editorial

References (10)

1. Sylvester RJ, van derMeijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patientswith stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
2. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
3. Van Rhijn BWG, Zuiverloon TCM, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58:433-41.
4. Sakano S, Matsuyama H, Takai K, et al. Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumors: validation study on the European Association of Urology guidelines. BJUInt 2010;107: 1598-604.
5. Hernandez V, De La Pena E, Martin MD, Blazquez C, Diaz FJ, Llorente C. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol. In press. DOI:10.1007/s00345- 010-0635-2.
6. Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol 2011;60:423-30.
7. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009;182:2195-203.
8. Lotan Y. Role of biomarkers to predict outcomes and response to therapy. Urol Oncol 2010;28:97-101.
9. Sylvester RJ. Combining a molecular profile with a clinical and pathological profile: biostatistical considerations. Scand J Urol Nephrol 2008;42(Suppl 218):185-90.
10. Lee JS, Leem SH, Lee SY, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010;28:2660-7.